1. GPCR/G Protein
    Neuronal Signaling
  2. mAChR

(-)-Cevimeline hydrochloride hemihydrate 

Cat. No.: HY-76772B
Handling Instructions

Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome.

For research use only. We do not sell to patients.

(-)-Cevimeline hydrochloride hemihydrate Chemical Structure

(-)-Cevimeline hydrochloride hemihydrate Chemical Structure

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 2262 In-stock
Estimated Time of Arrival: December 31
1 mg USD 840 In-stock
Estimated Time of Arrival: December 31
5 mg USD 3240 In-stock
Estimated Time of Arrival: December 31
10 mg   Get quote  
50 mg   Get quote  

* Please select Quantity before adding items.

Other Forms of (-)-Cevimeline hydrochloride hemihydrate:

  • Biological Activity

  • Technical Information

  • Purity & Documentation

Description

Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other tissues were investigated in mice, rats, guinea pigs, rabbits, and dogs. The in vitro metab. of SNI-2011 was also evaluated with rat and dog liver microsomes. After oral administration, plasma concns. of SNI-2011 reached to Cmax within 1 h in both species, suggesting that SNI-2011 was quickly absorbed, and then decreased with a t1/2 of 0.4-1.1 h. The bioavailability was 50% and 30% in rats and dogs, resp. Major metabolites in plasma were both S- and N-oxidized metabolites in rats and only N-oxidized metabolite in dogs, indicating that a large species difference was obsd. in the metab. of SNI-2011. Sex difference was also obsd. in the pharmacokinetics of SNI-2011 in rats, but not in dogs. In the in vitro study, chem. inhibition and pH-dependent studies revealed that the sulfoxidn. and N-oxidn. of SNI-2011 were mediated by cytochrome P 450 (CYP) and flavin-contg. monooxygenase (FMO), resp., in both species. In addn., CYP2D and CYP3A were mainly responsible for the sulfoxidn. in rat liver microsomes.

Solvent & Solubility
In Vitro: 

10 mM in DMSO

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 4.0853 mL 20.4265 mL 40.8530 mL
5 mM 0.8171 mL 4.0853 mL 8.1706 mL
10 mM 0.4085 mL 2.0427 mL 4.0853 mL
*Please refer to the solubility information to select the appropriate solvent.
Molecular Weight

244.78

Formula

C₁₀H₁₇NOS.HCl.₁/₂H₂O

SMILES

C[[email protected]@H](SC1)O[[email protected]@]21CN3CCC2CC3.Cl.[0.5H2O]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

  • 入库 高博建议小包装 1mg,$700; 5mg, $2700
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
(-)-Cevimeline hydrochloride hemihydrate
Cat. No.:
HY-76772B
Quantity:

(-)-Cevimeline hydrochloride hemihydrate

Cat. No.: HY-76772B